NTMir's mission is to save and improve lives through research, education, early detection, and improved treatments for people with pulmonary nontuberculous mycobacterial (NTM) disease.

Strategic Plan

  • Rapid Information Pilot Studies (RIPS)™, an innovative program that provides guidance about pressing research issues to secure large-scale research funding.
  • Work with patient support groups who participate in the NTMir mission.
  • Minimize lung damage associated with bronchiectasis and inflammation by supporting basic science, including the development of new medications, geared toward the treatment of NTM disease.
  • Support multi-centered initiatives to benefit NTM patients, physicians and researchers.
  • Engage patients and physicians in our goal to increase awareness of NTM among government agencies, industry, insurance companies, and laboratories.
  • NTMir will provide leadership at the national level to meet all goals through inclusive collaborative efforts, education and advocacy.

Board Members

Mary Allyn
Director Sarasota, FL
Amy Cherrnay
Dallas, TX
Elizabeth Glaeser

New York, NY

Michael Iseman, MD National Jewish Health Denver, CO

Connie Kazanjian

Miami, FL
Fern Leitman
Patient, Co-Founder & Treasurer
Miami, FL
Philip Leitman
President & Co-Founder Miami, FL

Medical and Scientific Advisory Committee

Timothy Aksamit, MD Mayo Clinic Rochester, MN
David Ashkin, MD A.G. Holley Hospital Lantana, FL
Kevin Fennelly, MD University of Florida College of Medicine Gainesville, FL
David Griffith, MD University of Texas Tyler, TX
Michael Iseman, MD National Jewish Medical & Research Center

Denver, CO

Richard Wallace, MD University of Texas Tyler, TX